J L Slack

Summary

Affiliation: Roswell Park Cancer Institute
Country: USA

Publications

  1. ncbi Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129
    J L Slack
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Blood 95:398-403. 2000
  2. ncbi Current issues in the management of acute promyelocytic leukemia
    J L Slack
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Ann Hematol 79:227-38. 2000
  3. ncbi Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study
    J L Slack
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Clin Oncol 15:1786-95. 1997
  4. ncbi Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARalpha mRNA using real-time reverse-transcription polymerase chain reaction
    J L Slack
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    J Mol Diagn 3:141-9. 2001
  5. ncbi Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia
    M E Rusiniak
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Res 60:1824-9. 2000
  6. ncbi Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin
    M Simon
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Bone Marrow Transplant 27:627-33. 2001
  7. ncbi HLA-DR antigen-negative acute myeloid leukemia
    M Wetzler
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Leukemia 17:707-15. 2003
  8. ncbi Use of nonvolume-reduced (unmanipulated after thawing) umbilical cord blood stem cells for allogeneic transplantation results in safe engraftment
    T Hahn
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Bone Marrow Transplant 32:145-50. 2003

Detail Information

Publications8

  1. ncbi Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129
    J L Slack
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Blood 95:398-403. 2000
    ..Blood. 2000;95:398-403)..
  2. ncbi Current issues in the management of acute promyelocytic leukemia
    J L Slack
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Ann Hematol 79:227-38. 2000
    ....
  3. ncbi Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study
    J L Slack
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Clin Oncol 15:1786-95. 1997
    ....
  4. ncbi Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARalpha mRNA using real-time reverse-transcription polymerase chain reaction
    J L Slack
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    J Mol Diagn 3:141-9. 2001
    ....
  5. ncbi Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia
    M E Rusiniak
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Res 60:1824-9. 2000
    ..Treatment of APL blasts in vitro with all-trans-RA resulted in up-regulation of B94 mRNA. These results suggest that B94 plays a role in myeloid development and support the hypothesis that B94 is a target gene of PML-RARalpha in APL...
  6. ncbi Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin
    M Simon
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Bone Marrow Transplant 27:627-33. 2001
    ..Prospective randomized trials of Hep vs LMWH vs placebo are warranted to assess the efficacy of heparin compounds in the prevention of VOD...
  7. ncbi HLA-DR antigen-negative acute myeloid leukemia
    M Wetzler
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Leukemia 17:707-15. 2003
    ..The diagnosis of APL cannot be based on morphology and lack of HLA-DR antigen expression; rather, it requires cytogenetic or molecular confirmation...
  8. ncbi Use of nonvolume-reduced (unmanipulated after thawing) umbilical cord blood stem cells for allogeneic transplantation results in safe engraftment
    T Hahn
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Bone Marrow Transplant 32:145-50. 2003
    ..4-95.6) and 22.5% (95% CI, 0-58.7). There was no serious toxicity from UCB infusion using unmanipulated UCB units. We conclude that unmanipulated UCB units may be infused safely into UCBT patients with adequate engraftment and survival...